Analysts Issue Forecasts for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at B. Riley issued their FY2024 earnings per share estimates for Nektar Therapeutics in a report released on Tuesday, January 7th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of ($0.83) per share for the year. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

A number of other research firms have also issued reports on NKTR. BTIG Research reiterated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. HC Wainwright assumed coverage on Nektar Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $6.50 target price for the company. Finally, Piper Sandler assumed coverage on Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target on the stock. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Price Performance

Shares of NASDAQ:NKTR opened at $1.03 on Friday. The firm’s 50-day moving average is $1.09 and its two-hundred day moving average is $1.21. Nektar Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.93. The firm has a market capitalization of $189.99 million, a PE ratio of -1.23 and a beta of 0.59.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NKTR. Samlyn Capital LLC acquired a new position in Nektar Therapeutics during the second quarter worth $11,728,000. Eventide Asset Management LLC increased its holdings in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after purchasing an additional 1,870,904 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Nektar Therapeutics by 56.1% in the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares during the period. Nantahala Capital Management LLC boosted its holdings in Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after buying an additional 1,634,046 shares in the last quarter. Finally, State Street Corp grew its position in Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after buying an additional 355,759 shares during the period. Institutional investors and hedge funds own 75.88% of the company’s stock.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the sale, the chief executive officer now directly owns 1,195,710 shares of the company’s stock, valued at approximately $1,207,667.10. This trade represents a 3.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now owns 351,892 shares of the company’s stock, valued at $316,702.80. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 155,575 shares of company stock valued at $149,878 over the last ninety days. Insiders own 3.71% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.